- Home
- DRRX vs CANF Comparison
DRRX vs CANF Comparison
Compare DRRX & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRRX
- CANF
- Stock Information
- Founded
- DRRX 1998
- CANF 1994
- Country
- DRRX United States
- CANF Israel
- Employees
- DRRX N/A
- CANF N/A
- Industry
- DRRX Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- DRRX Health Care
- CANF Health Care
- Exchange
- DRRX Nasdaq
- CANF Nasdaq
- Market Cap
- DRRX N/A
- CANF 7.9M
- IPO Year
- DRRX 2000
- CANF N/A
- Fundamental
- Price
- DRRX $0.70
- CANF $1.17
- Analyst Decision
- DRRX Hold
- CANF Strong Buy
- Analyst Count
- DRRX 1
- CANF 2
- Target Price
- DRRX N/A
- CANF $14.00
- AVG Volume (30 Days)
- DRRX 54.0K
- CANF 412.3K
- Earning Date
- DRRX 05-12-2025
- CANF 05-06-2025
- Dividend Yield
- DRRX N/A
- CANF N/A
- EPS Growth
- DRRX N/A
- CANF N/A
- EPS
- DRRX N/A
- CANF N/A
- Revenue
- DRRX $2,031,000.00
- CANF $674,000.00
- Revenue This Year
- DRRX N/A
- CANF $461.72
- Revenue Next Year
- DRRX $935.93
- CANF N/A
- P/E Ratio
- DRRX N/A
- CANF N/A
- Revenue Growth
- DRRX N/A
- CANF N/A
- 52 Week Low
- DRRX $0.67
- CANF $1.22
- 52 Week High
- DRRX $1.88
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- DRRX 37.40
- CANF 37.12
- Support Level
- DRRX $0.67
- CANF $1.14
- Resistance Level
- DRRX $0.75
- CANF $1.27
- Average True Range (ATR)
- DRRX 0.05
- CANF 0.12
- MACD
- DRRX -0.00
- CANF -0.02
- Stochastic Oscillator
- DRRX 20.00
- CANF 4.46
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).